These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31024443)

  • 1. Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients.
    Villagelin D; Romaldini J; Andrade J; Santos R; Milkos A; Teixeira PFDS; Ward LS
    Front Endocrinol (Lausanne); 2019; 10():192. PubMed ID: 31024443
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the Graves' Orbitopathy-Specific Quality of Life Questionnaire in the Mainland Chinese Population.
    Zeng P; Fan SX; Li ZJ; Peng YY; Hu YX; Xu MT; Wang M
    J Ophthalmol; 2019; 2019():7602419. PubMed ID: 31011452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
    Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)].
    Nowak M; Marek B; Kos-Kudła B; Siemińska L; Londzin-Olesik M; Głogowska-Szeląg J; Nowak W; Kajdaniuk D
    Endokrynol Pol; 2022; 73(4):756-777. PubMed ID: 36059167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves' orbitopathy.
    Stoynova MA; Shinkov AD; Dimitrova ID; Yankova IA; Kovatcheva RD
    Int Ophthalmol; 2024 Feb; 44(1):68. PubMed ID: 38347322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Graves' ophthalmopathy-specific quality of life in Korean patients.
    Choi YJ; Lim HT; Lee SJ; Lee SY; Yoon JS
    Eye (Lond); 2012 Apr; 26(4):544-51. PubMed ID: 22241019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Ocular Surface Irritation Symptoms in Inactive Mild and Moderate-to-Severe Graves' Orbitopathy.
    Yu Y; Hu YX; Lu MX; Ouyang ZL; Xu MT; Zhao LY; Wang M
    Ophthalmol Ther; 2024 Apr; 13(4):1015-1024. PubMed ID: 38376797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GO-QOL--disease-specific quality of life questionnaire in Graves' orbitopathy.
    Sawicka-Gutaj N; Bednarczuk T; Daroszewski J; Waligórska-Stachura J; Miśkiewicz P; Sowiński J; Bolanowski M; Ruchała M
    Endokrynol Pol; 2015; 66(4):362-6. PubMed ID: 26323474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the quality of life in Indian Graves' orbitopathy patients and validation of Hindi version of GO-QOL questionnaire.
    Delampady K; Reddy SVB; Yadav SB
    Indian J Ophthalmol; 2020 Aug; 68(8):1617-1621. PubMed ID: 32709791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement.
    Perros P; Hegedüs L; Bartalena L; Marcocci C; Kahaly GJ; Baldeschi L; Salvi M; Lazarus JH; Eckstein A; Pitz S; Boboridis K; Anagnostis P; Ayvaz G; Boschi A; Brix TH; Currò N; Konuk O; Marinò M; Mitchell AL; Stankovic B; Törüner FB; von Arx G; Zarković M; Wiersinga WM
    Orphanet J Rare Dis; 2017 Apr; 12(1):72. PubMed ID: 28427469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Factors for Changes in Quality of Life after Steroid Treatment for Active Moderate-to-Severe Graves' Orbitopathy: A Prospective Trial.
    Hoppe E; Lee ACH; Hoppe D; Kahaly GJ
    Eur Thyroid J; 2021 Feb; 9(6):313-320. PubMed ID: 33718255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid volume and severity of Graves' orbitopathy.
    Profilo MA; Sisti E; Marcocci C; Vitti P; Pinchera A; Nardi M; Rocchi R; Latrofa F; Menconi F; Altea MA; Leo M; Rago T; Marinò M
    Thyroid; 2013 Jan; 23(1):97-102. PubMed ID: 23088654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
    Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
    Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Ophthalmic Surgery for Graves' Orbitopathy on Quality of Life: A Systematic Review and Meta-Analysis.
    Woo T; Li C; Ganesananthan S; Rajendram R; Uddin J; Lee RWJ; Dayan C; Taylor P
    Thyroid; 2022 Feb; 32(2):177-187. PubMed ID: 34877883
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and psychometric properties of the Thai Graves' ophthalmopathy quality of life (GO-QOL) questionnaire.
    Lumyongsatien M; Keeratidamkerngsakul B; Pornpanich K; Vangveeravong S; Saonanon P; Wiwatwongwana D; Mahaisavariya P; Aryasit O; Pongpirul K
    J Patient Rep Outcomes; 2019 Dec; 4(1):1. PubMed ID: 31893319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012.
    Perros P; Žarković M; Azzolini C; Ayvaz G; Baldeschi L; Bartalena L; Boschi A; Bournaud C; Brix TH; Covelli D; Ćirić S; Daumerie C; Eckstein A; Fichter N; Führer D; Hegedüs L; Kahaly GJ; Konuk O; Lareida J; Lazarus J; Leo M; Mathiopoulou L; Menconi F; Morris D; Okosieme O; Orgiazzi J; Pitz S; Salvi M; Vardanian-Vartin C; Wiersinga W; Bernard M; Clarke L; Currò N; Dayan C; Dickinson J; Knežević M; Lane C; Marcocci C; Marinò M; Möller L; Nardi M; Neoh C; Pearce S; von Arx G; Törüner FB
    Br J Ophthalmol; 2015 Nov; 99(11):1531-5. PubMed ID: 25953846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement Properties of the Persian Translated Version of Graves Orbitopathy Quality of Life Questionnaire: A Validation Study.
    Kashkouli MB; Karimi N; Aghamirsalim M; Abtahi MB; Nojomi M; Shahrad-Bejestani H; Salehi M
    Ophthalmic Epidemiol; 2017 Feb; 24(1):3-10. PubMed ID: 28001456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.